Sulzer to start trials on bone growth protein:
This article was originally published in Clinica
Executive Summary
Sulzer Medica will begin US clinical trials to examine whether its bone growth protein can repair bone loss associated with periodontal disease. Consisting of a mixture of naturally occurring bone growth factors in a collagen matrix, Ne-Osteo, a bone morphogenic protein (BMP), promotes bone growth. Sulzer Orthopedics Biologics is working with Sulzer Calcitek to develop applications of the Ne-Osteo BMP technology for dental use. Sulzer expects its market in dentistry to grow to $300 million within the next ten years.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.